Full Text Journal Articles by
Author Miles Fisher

Advertisement

Find full text journal articles






A post-hoc pooled analysis to evaluate the risk of hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus 100 U/mL (Gla-100) over wider nocturnal windows in individuals with type 2 diabetes on a basal-only insulin regimen.

Geremia B Bolli, Carol Wysham, Miles Fisher, Soazig Chevalier, Anna M G Cali, Bruno Leroy, Matthew C Riddle,

The EDITION trials in type 2 diabetes demonstrated comparable glycaemic control with less nocturnal and anytime (24-hour) hypoglycaemia for insulin glargine 300 U/mL (Gla-300) versus glargine 100 U/mL (Gla-100). However, the predefined nocturnal window (0:00-5:59 AM) may not be the most relevant for clinical practice. This post-hoc analysis compared expansions ... Read more >>

Diabetes Obes Metab (Diabetes, obesity & metabolism)
[2019, 21(2):402-407]

Cited: 0 times

View full text PDF listing >>



Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.

Rury R Holman, Ruth L Coleman, Juliana C N Chan, Jean-Louis Chiasson, Huimei Feng, Junbo Ge, Hertzel C Gerstein, Richard Gray, Yong Huo, Zhihui Lang, John J McMurray, Lars Rydén, Stefan Schröder, Yihong Sun, Michael J Theodorakis, Michal Tendera, Lynne Tucker, Jaakko Tuomilehto, Yidong Wei, Wenying Yang, Duolao Wang, Dayi Hu, Changyu Pan, ,

BACKGROUND:The effect of the α-glucosidase inhibitor acarbose on cardiovascular outcomes in patients with coronary heart disease and impaired glucose tolerance is unknown. We aimed to assess whether acarbose could reduce the frequency of cardiovascular events in Chinese patients with established coronary heart disease and impaired glucose tolerance, and whether the ... Read more >>

Lancet Diabetes Endocrinol (The lancet. Diabetes & endocrinology)
[2017, 5(11):877-886]

Cited: 24 times

View full text PDF listing >>



Advertisement

Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twice-daily basal insulin to once-daily insulin glargine 300 U/mL or insulin glargine 100 U/mL (EDITION 1 and EDITION 2 subgroup analysis).

Ronan Roussel, Michael C d'Emden, Miles Fisher, F Javier Ampudia-Blasco, Peter Stella, Florence Bizet, Anna M G Cali, Carol H Wysham,

In this post hoc analysis we compared glycaemic control and hypoglycaemia between insulin glargine 300 U/mL (Gla-300) and glargine 100 U/mL (Gla-100) administered once daily in people with type 2 diabetes (T2DM) from the EDITION 1 (basal plus mealtime insulin) and EDITION 2 (basal insulin plus oral antihyperglycaemic drugs) trials ... Read more >>

Diabetes Obes Metab (Diabetes, obesity & metabolism)
[2018, 20(2):448-452]

Cited: 1 time

View full text PDF listing >>



Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.

Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews, ,

Background Canagliflozin is a sodium-glucose cotransporter 2 inhibitor that reduces glycemia as well as blood pressure, body weight, and albuminuria in people with diabetes. We report the effects of treatment with canagliflozin on cardiovascular, renal, and safety outcomes. Methods The CANVAS Program integrated data from two trials involving a total ... Read more >>

N. Engl. J. Med. (The New England journal of medicine)
[2017, 377(7):644-657]

Cited: 651 times

View full text PDF listing >>



2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR).

, Massimo F Piepoli, Arno W Hoes, Stefan Agewall, Christian Albus, Carlos Brotons, Alberico L Catapano, Marie-Therese Cooney, Ugo Corrà, Bernard Cosyns, Christi Deaton, Ian Graham, Michael Stephen Hall, F D Richard Hobbs, Maja-Lisa Løchen, Herbert Löllgen, Pedro Marques-Vidal, Joep Perk, Eva Prescott, Josep Redon, Dimitrios J Richter, Naveed Sattar, Yvo Smulders, Monica Tiberi, H Bart van der Worp, Ineke van Dis, W M Monique Verschuren, , , Guy De Backer, Marco Roffi, Victor Aboyans, Norbert Bachl, Héctor Bueno, Scipione Carerj, Leslie Cho, John Cox, Johan De Sutter, Günther Egidi, Miles Fisher, Donna Fitzsimons, Oscar H Franco, Maxime Guenoun, Catriona Jennings, Borut Jug, Paulus Kirchhof, Kornelia Kotseva, Gregory Y H Lip, François Mach, Giuseppe Mancia, Franz Martin Bermudo, Alessandro Mezzani, Alexander Niessner, Piotr Ponikowski, Bernhard Rauch, Lars Rydén, Adrienne Stauder, Guillaume Turc, Olov Wiklund, Stephan Windecker, Jose Luis Zamorano,

Eur J Prev Cardiol (European journal of preventive cardiology)
[2016, 23(11):NP1-NP96]

Cited: 219 times

View full text PDF listing >>



Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes.

G Fulcher, D R Matthews, V Perkovic, D de Zeeuw, K W Mahaffey, C Mathieu, V Woo, C Wysham, G Capuano, M Desai, W Shaw, F Vercruysse, G Meininger, B Neal, ,

To assess the efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes enrolled in the CANagliflozin cardioVascular Assessment Study (CANVAS) who were on an incretin mimetic [dipeptidyl peptidase-4 (DPP-4) inhibitor or glucagon-like peptide-1 (GLP-1) receptor agonist].CANVAS is a double-blind, placebo-controlled study ... Read more >>

Diabetes Obes Metab (Diabetes, obesity & metabolism)
[2016, 18(1):82-91]

Cited: 34 times

View full text PDF listing >>



Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis.

Miles Fisher, Mark C Petrie, Philip D Ambery, Jill Donaldson, June Ye, John J V McMurray,

Albiglutide is a glucagon-like peptide-1 receptor agonist, a new class of drugs used to treat type 2 diabetes. We did a prospective meta-analysis of the cardiovascular safety of albiglutide as stipulated by the US Food and Drug Administration recommendations for the assessment of new treatments for diabetes.We did a meta-analysis ... Read more >>

Lancet Diabetes Endocrinol (The lancet. Diabetes & endocrinology)
[2015, 3(9):697-703]

Cited: 27 times

View full text PDF listing >>



Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial.

David Preiss, Suzanne M Lloyd, Ian Ford, John J McMurray, Rury R Holman, Paul Welsh, Miles Fisher, Chris J Packard, Naveed Sattar,

Metformin reduces cardiovascular risk in patients with type 2 diabetes seemingly independent of lowering blood glucose concentration. We assessed the cardiovascular effects of metformin in individuals without type 2 diabetes.We did a single-centre, double-blind, placebo-controlled trial at the Glasgow Clinical Research Facility (Glasgow, UK). We enrolled patients taking statins who ... Read more >>

Lancet Diabetes Endocrinol (The lancet. Diabetes & endocrinology)
[2014, 2(2):116-124]

Cited: 51 times

View full text PDF listing >>



Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical trial.

B W Bode, J B Buse, M Fisher, S K Garg, M Marre, L Merker, E Renard, D L Russell-Jones, C T Hansen, A Rana, S R Heller, ,

AIMS: The goal of this study was to compare the long-term safety and efficacy of the basal insulin analogue, insulin degludec with insulin glargine (both with insulin aspart) in Type 1 diabetes, over a 2-year time period. METHODS: This open-label trial comprised a 1-year main trial and a 1-year extension. Patients ... Read more >>

Diabet. Med. (Diabetic medicine : a journal of the British Diabetic Association)
[2013, 30(11):1293-1297]

Cited: 48 times

View full text PDF listing >>



Alogliptin after acute coronary syndrome in patients with type 2 diabetes.

William B White, Christopher P Cannon, Simon R Heller, Steven E Nissen, Richard M Bergenstal, George L Bakris, Alfonso T Perez, Penny R Fleck, Cyrus R Mehta, Stuart Kupfer, Craig Wilson, William C Cushman, Faiez Zannad, ,

To assess potentially elevated cardiovascular risk related to new antihyperglycemic drugs in patients with type 2 diabetes, regulatory agencies require a comprehensive evaluation of the cardiovascular safety profile of new antidiabetic therapies. We assessed cardiovascular outcomes with alogliptin, a new inhibitor of dipeptidyl peptidase 4 (DPP-4), as compared with placebo ... Read more >>

N. Engl. J. Med. (The New England journal of medicine)
[2013, 369(14):1327-1335]

Cited: 942 times

View full text PDF listing >>



Beryllium disease among construction trade workers at Department of Energy nuclear sites.

Laura S Welch, Knut Ringen, John Dement, Eula Bingham, Patricia Quinn, Janet Shorter, Miles Fisher,

BACKGROUND: A medical surveillance program was developed to identify current and former construction workers at significant risk for beryllium related disease from work at the DOE nuclear weapons facilities, and to improve surveillance among beryllium exposed workers. METHODS: Medical examinations included a medical history and a beryllium blood lymphocyte proliferation ... Read more >>

Am. J. Ind. Med. (American journal of industrial medicine)
[2013, 56(10):1125-1136]

Cited: 8 times

View full text PDF listing >>



[European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts)].

Joep Perk, Guy De Backer, Helmut Gohlke, Ian Graham, Zeljko Reiner, W M Monique Verschuren, Christian Albus, Pascale Benlian, Gudrun Boysen, Renata Cifkova, Christi Deaton, Shah Ebrahim, Miles Fisher, Giuseppe Germanò, Richard Hobbs, Arno Hoes, Sehnaz Karadeniz, Alessandro Mezzani, Eva Prescott, Lars Ryden, Martin Scherer, Mikko Syvanne, Wilma J M Scholte Op Reimer, Christiaan Vrints, David Wood, Jose Luis Zamorano, Faiez Zannad, ,

G Ital Cardiol (Rome) (Giornale italiano di cardiologia (2006))
[2013, 14(5):328-392]

Cited: 22 times

View full text PDF listing >>



European guidelines on cardiovascular disease prevention in clinical practice (version 2012) : the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts).

Joep Perk, Guy De Backer, Helmut Gohlke, Ian Graham, Zeljko Reiner, W M Monique Verschuren, Christian Albus, Pascale Benlian, Gudrun Boysen, Renata Cifkova, Christi Deaton, Shah Ebrahim, Miles Fisher, Giuseppe Germano, Richard Hobbs, Arno Hoes, Sehnaz Karadeniz, Alessandro Mezzani, Eva Prescott, Lars Ryden, Martin Scherer, Mikko Syvänne, Wilma J M Scholte Op Reimer, Christiaan Vrints, David Wood, Jose Luis Zamorano, Faiez Zannad, ,

Int J Behav Med (International journal of behavioral medicine)
[2012, 19(4):403-488]

Cited: 93 times

View full text PDF listing >>



[European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)].

Joep Perk, Guy De Backer, Helmut Gohlke, Ian Graham, Željko Reiner, Monique Verschuren, Christian Albus, Pascale Benlian, Gudrun Boysen, Renata Cifkova, Christi Deaton, Shah Ebrahim, Miles Fisher, Giuseppe Germano, Richard Hobbs, Arno Hoes, Sehnaz Karadeniz, Alessandro Mezzani, Eva Prescott, Lars Ryden, Martin Scherer, Syvänne Mikko, Wilma J M Scholte Op Reimer, Christiaan Vrints, David Wood, Jose Luis Zamorano, Faiez Zannad, , , , ,

Turk Kardiyol Dern Ars (Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir)
[2012, 40 Suppl 3:1-76]

Cited: 0 times

View full text PDF listing >>



European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts).

, , , , , , , , , , , , , ,

Eur J Prev Cardiol (European journal of preventive cardiology)
[2012, 19(4):585-667]

Cited: 130 times

View full text PDF listing >>



European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts).

Joep Perk, Guy De Backer, Helmut Gohlke, Ian Graham, Zeljko Reiner, W M Monique Verschuren, Christian Albus, Pascale Benlian, Gudrun Boysen, Renata Cifkova, Christi Deaton, Shah Ebrahim, Miles Fisher, Giuseppe Germano, Richard Hobbs, Arno Hoes, Sehnaz Karadeniz, Alessandro Mezzani, Eva Prescott, Lars Ryden, Martin Scherer, Mikko Syvänne, Wilma J M Scholte Op Reimer, Christiaan Vrints, David Wood, Jose Luis Zamorano, Faiez Zannad, , ,

Atherosclerosis (Atherosclerosis)
[2012, 223(1):1-68]

Cited: 160 times

View full text PDF listing >>



European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts).

Joep Perk, Guy De Backer, Helmut Gohlke, Ian Graham, Zeljko Reiner, Monique Verschuren, Christian Albus, Pascale Benlian, Gudrun Boysen, Renata Cifkova, Christi Deaton, Shah Ebrahim, Miles Fisher, Giuseppe Germano, Richard Hobbs, Arno Hoes, Sehnaz Karadeniz, Alessandro Mezzani, Eva Prescott, Lars Ryden, Martin Scherer, Mikko Syvänne, Wilma J M Scholte op Reimer, Christiaan Vrints, David Wood, Jose Luis Zamorano, Faiez Zannad, , ,

Eur. Heart J. (European heart journal)
[2012, 33(13):1635-1701]

Cited: 1643 times

View full text PDF listing >>



Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.

Simon Heller, John Buse, Miles Fisher, Satish Garg, Michel Marre, Ludwig Merker, Eric Renard, David Russell-Jones, Areti Philotheou, Ann Marie Ocampo Francisco, Huiling Pei, Bruce Bode, ,

BACKGROUND: Intensive basal-bolus insulin therapy has been shown to improve glycaemic control and reduce the risk of long-term complications that are associated with type 1 diabetes mellitus. Insulin degludec is a new, ultra-longacting basal insulin. We therefore compared the efficacy and safety of insulin degludec and insulin glargine, both administered ... Read more >>

Lancet (Lancet (London, England))
[2012, 379(9825):1489-1497]

Cited: 168 times

View full text PDF listing >>



Pharmacologic management of patients with both heart failure and diabetes.

Michael R MacDonald, Mark C Petrie, Miles Fisher, John J V McMurray,

Diabetes and heart failure often occur together in patients, with each condition influencing the treatment of the other. Each disease has its own well-documented impact on prognosis, but when they are present in the same patient, the risk of morbidity and mortality increases substantially. Some therapies used in the treatment ... Read more >>

Curr Heart Fail Rep (Current heart failure reports)
[2009, 6(2):126-132]

Cited: 1 time

View full text PDF listing >>



Diabetes, left ventricular systolic dysfunction, and chronic heart failure.

Michael R MacDonald, Mark C Petrie, Nathaniel M Hawkins, John R Petrie, Miles Fisher, Robert McKelvie, David Aguilar, Henry Krum, John J V McMurray,

Chronic heart failure (HF) and diabetes mellitus (DM) commonly coexist. Each condition increases the likelihood of developing the other, and when they occur together in the same patient the risk of morbidity and mortality increases markedly. We discuss the epidemiological overlap and consider the complex patho-physiological pathways linking the two ... Read more >>

Eur. Heart J. (European heart journal)
[2008, 29(10):1224-1240]

Cited: 85 times

View full text PDF listing >>



Prevalence of symptoms and signs of shoulder problems in people with diabetes mellitus.

Simon J Thomas, Claire McDougall, Iain D M Brown, Marie-Claire Jaberoo, Adam Stearns, Raihan Ashraf, Miles Fisher, Ian G Kelly,

Diabetes mellitus is a known risk factor for frozen shoulder. This study was performed to quantify this association and test any relationship with other risk factors for diabetic complications. Patients attending diabetic (n = 865) and general medical (n = 202) clinics were interviewed and examined. External rotation was measured ... Read more >>

J Shoulder Elbow Surg (Journal of shoulder and elbow surgery)
[2007, 16(6):748-751]

Cited: 48 times

View full text PDF listing >>



[Metabolic control by means of insulin in patients with type 2 diabetes and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity--secondary publication].

Ida Gustafsson, Klas Malmberg, Lars Rydén, Hans Wedel, Kåre Birkeland, Aart Bootsma, Kenneth Dickstein, Suad Efendic, Miles Fisher, Anders Hamsten, Johan Herlitz, Per Rossen Hildebrandt, Kenneth MacLeod, Markku Laakso, Christian T Torp-Pedersen, Anders Waldenström, ,

Patients with diabetes have an unfavourable prognosis after an acute myocardial infarction. The DIGAMI 2 study investigated the effect of various metabolic treatment strategies in type 2 diabetic patients with acute myocardial infarction: acutely introduced, long-term insulin treatment did not improve survival when compared with conventional management at similar levels ... Read more >>

Ugeskr. Laeg. (Ugeskrift for laeger)
[2006, 168(6):581-584]

Cited: 0 times

View full text PDF listing >>



Thiazolidinediones in patients with diabetes mellitus and heart failure : implications of emerging data.

David P Macfarlane, Miles Fisher,

Individuals with diabetes mellitus have an increased risk of developing heart failure, usually as a consequence of coronary artery disease, although a specific diabetic cardiomyopathy, secondary to a microangiopathy, may also exist. The thiazolidinediones, a relatively new class of insulin-sensitizing agents used in the management of type 2 diabetes mellitus, ... Read more >>

Am J Cardiovasc Drugs (American journal of cardiovascular drugs : drugs, devices, and other interventions)
[2006, 6(5):297-304]

Cited: 9 times

View full text PDF listing >>



Promoting and maintaining physical activity in people with type 2 diabetes.

Alison F Kirk, Nanette Mutrie, Paul D Macintyre, Miles B Fisher,

BACKGROUND: Limited research has investigated how to promote physical activity in people with type 2 diabetes. This study evaluated physical activity counseling over 12 months in people with type 2 diabetes. DESIGN: Participants were given standard exercise information and randomly assigned to receive physical activity counseling or not. Data were ... Read more >>

Am J Prev Med (American journal of preventive medicine)
[2004, 27(4):289-296]

Cited: 53 times

View full text PDF listing >>



Effect of controlling hyperglycemia with diet on QT abnormalities in newly diagnosed patients with type 2 diabetes.

Rajeev Kumar, Miles Fisher, Rhinnanon Whitaker, Peter W Macfarlane,

Diabetes Care (Diabetes care)
[2004, 27(11):2767-2768]

Cited: 2 times

View full text PDF listing >>



Advertisement

Disclaimer
2.9039 s